Oct 05, 2024, 10:19:27 AM IST
![]()
Here's a list of 7 small & midcap stocks that can rally up to 27%, according to Axis Securities:
Getty Images
![]()
2/8
Aurobindo Pharma | CMP: Rs 1464
"Aurobindo has already invested Rs 7,000 Cr in Capex over the last two years, primarily in segments like Biosimilars and Pen-G (API). Aurobindo’ valuations in the coming years will be influenced by the return on invested capital (ROIC) generated from this Capex," Axis Securities said.
ETMarkets.com
![]()
"New launches in the US market like Darunavir and Spiriva have gained market shares of up to 30% and 25% respectively. The recent launch approval of gMegabran has the potential to add yearly incremental sales of $50 Mn. Recent approvals for Tolvaptan (market size $287 Mn) and Xyway (market size $958 Mn with 180 days exclusivity, could add business in the second half. Double-digit growth in the India business is expected as the company has already increased MR (Medical Representative) numbers to 1,000," it said.
ETMarkets.com
![]()
4/8
Dalmia Bharat | CMP: Rs 1928
"Given the company's superior positioning in key markets in the East and South, exposure to the West region, the government's focus on infrastructure and affordable housing, increasing real estate demand, new capacity ramp-up, and ongoing cost optimization measures, DBL is expected to deliver stable performance. The company is projected to grow its Volume/Revenue/EBITDA/APAT at a CAGR of 9%/8%/11%/21% over FY24-FY26E," it said.
ETMarkets.com
![]()
5/8
Federal Bank | CMP: Rs 194
"While we believe FB remains well positioned to deliver a sustainable RoA of 1.3%, improving NIMs backed by shifting portfolio mix towards higher-yielding products would be a key enabler for the bank to deliver RoA of 1.4% and would drive the next leg of stock re-rating. We expect FB to deliver RoA/RoE of 1.3-1.4%/14-16% over FY25-27E supported by steady NIMs, gradually improving the Opex ratio and stable credit costs (~30-35bps)," it said.
ETMarkets.com
![]()
6/8
Prestige Estates Projects | CMP: Rs 1744
"Our recommendation is supported by a diversified business model, execution supremacy, robust order book, and strengthening annuity streams," it said.
Agencies
![]()
7/8
Sansera Engineering | CMP: Rs 1623
"In light of attributes such as a) Higher sales mix in Non-Auto ICE components, b) Higher International business (exports), c) Focused approach on improving margin trends, d) The company’s capability to generate strong operating cash flows, and e) Capacity expansion plans, we expect Revenue, EBITDA, and PAT to grow at CAGRs of 17%, 20% and 22% respectively over FY24-26E," it said.
ETMarkets.com
![]()
8/8
J Kumar Infraprojects | CMP: Rs 748
"The company reported good operating performance in Q1FY25 with Revenue/EBITDA/PAT growth of 13%/14%/19% which were in line with estimates. Considering strong and diversified order book position, healthy bidding pipeline, new order inflows, emerging opportunities in the construction space, the company’s efficient and timely execution and strong financial credence, we expect JKIL to report Revenue/EBITDA/APAT CAGR of 16%/18%/22% respectively over FY24-FY26E," it said.
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
Reuters

2 years ago
143
English (US)